AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33634446
Drug: Restarting oral
RxNorm normalized name: levonorgestrel
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Restarting oral anticoagulation
Trial: 34133836
Drug: 5% topical
RxNorm normalized name: BP 5% Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% topical minoxidil plus SULT1A1 enzyme booster
Trial: 34133836
Drug: 5% topical
RxNorm normalized name: BP 5% Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% topical minoxidil plus placebo adjuvant
Trial: 33573276
Drug: Single doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single doses of Pera orange juice
Trial: 33573276
Drug: Single doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single doses of Moro orange juice
Trial: 32539157
Drug: Brief intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief intervention plus referral to treatment
Trial: 32539157
Drug: Referral to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Referral to treatment only
Trial: 36347056
Drug: Integrase strand
RxNorm normalized name: Integrase strand transfer inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrase strand transfer inhibitor therapy
Trial: 36347056
Drug: Systemic inflammation,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic inflammation, astrocyte activation, and tryptophan metabolism pathways
Trial: 34489282
Drug: Standard informed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard informed consent (control arm) - includes full length trial PIS and administration of QuIC-A and QuIC-B.
Trial: 35269639
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg daily gluten intake
Trial: 33183258
Drug: Intravenous TXA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous TXA (1.0 g by intravenous injection before tourniquet inflation and before surgical incision closure)
Trial: 33183258
Drug: Topical TXA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical TXA (3.0 g in 75 mL physiological saline 5 min prior to final tourniquet release)
Trial: 35925043
Drug: Pembrolizumab in
RxNorm normalized name: pembrolizumab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab in combination with chemotherapy for neoadjuvant treatment and then as a single agent for adjuvant treatment.
Trial: 35925043
Drug: Placebo in
RxNorm normalized name: placebo INTRAVEN VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in combination with chemotherapy for neoadjuvant treatment and then as a single agent for adjuvant treatment.
Trial: 32139488
Drug: Oral felodipine
RxNorm normalized name: Felodipine
DrugBank: Felodipine (DB01023)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral felodipine in patients with coeliac disease (Group A, B+C, D)
Trial: 32139488
Drug: Oral felodipine
RxNorm normalized name: Felodipine
DrugBank: Felodipine (DB01023)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral felodipine with grapefruit juice in healthy individuals
Trial: 32139488
Drug: Oral felodipine
RxNorm normalized name: Felodipine
DrugBank: Felodipine (DB01023)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral felodipine with water in healthy individuals
Trial: 34251506
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (lopinavir-ritonavir and hydroxychloroquine)
Trial: 32629035
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no antiviral therapy)
Trial: 2006134578
Drug: Anisodamine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anisodamine 0.5 mg/(kg24 h) intravenously for 7 days
Trial: 35339911
Drug: Bright light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bright light therapy (BLT) 10,000 lux
Trial: 33241267
Drug: Sequential anti-tubercular
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential anti-tubercular treatment (ATT) regimen
Trial: 32911505
Drug: Increased perceived
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased perceived intrinsic cost of lying (treatment condition)
Trial: 35914303
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 0.05% cyclosporine and artificial tears (CS group)
Trial: 33721454
Drug: NIPS (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NIPS (oral S‐1 + intravenous and intraperitoneal chemotherapy with paclitaxel)
Trial: 33721454
Drug: Control (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (oral S‐1 + intravenous chemotherapy with oxaliplatin)
Trial: 33721454
Drug: NIPS (after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NIPS (after chemotherapy)
Trial: 32086925
Drug: Carbon nanoparticles
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbon nanoparticles suspension injected into the thyroid gland of trial group patients.
Trial: 32593895
Drug: HMB-enriched formula
RxNorm normalized name: STRESS FORMULA 500,BIOTIN ENRICHED TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HMB-enriched formula (calcium-HMB 1500 mg, L-arginine 7000 mg, L-glutamine 7000 mg per pack, 2 packs per day)
Trial: 33499843
Drug: 4DryField® PH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4DryField® PH (5 g, subfascially and subcutaneously during wound closure)
Trial: 34789504
Drug: Hybrid closed-loop
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hybrid closed-loop (HCL) insulin delivery during high-intensity exercise (HIE)
Trial: 34789504
Drug: Hybrid closed-loop
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hybrid closed-loop (HCL) insulin delivery during moderate-intensity exercise (MIE)
Trial: 34789504
Drug: Hybrid closed-loop
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hybrid closed-loop (HCL) insulin delivery during resistance exercise (RE)
Trial: 32928851
Drug: Rhythm and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhythm and Movement for Self-Regulation (RAMSR) intervention delivered by trained teachers during group time in kindergartens, daily for 8 weeks.
Trial: 34498352
Drug: 12-week multimodal
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12-week multimodal exercise-based program including supervised exercise twice weekly, protein supplement, home-based walking program, nurse-led support and counseling
Trial: 33555314
Drug: Rapid-tapering regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid-tapering regimen (immediate high-dose daily administration of prednisone, 0.75 mg/kg, followed by rapid decrease)
Trial: 33555314
Drug: Slow-tapering regimen
RxNorm normalized name: Slow-Fe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-tapering regimen (gradual increase to 1.5 mg/kg every other day and slow decrease)
Trial: 33555314
Drug: Rapid-tapering regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid-tapering regimen
Trial: 33555314
Drug: Slow-tapering regimen
RxNorm normalized name: Slow-Fe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-tapering regimen
Trial: 32311455
Drug: Paracetamol (aqueous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol (aqueous solution or suspension)
Trial: 32311455
Drug: Danazol (aqueous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danazol (aqueous suspension)
Trial: 32311455
Drug: Long-chain triglyceride
RxNorm normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-chain triglyceride solution of danazol
Trial: 36189651
Drug: Polynucleotide and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polynucleotide and hyaluronic acid-based gel
Trial: 34479364
Drug: Direct oral
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct oral anticoagulants (DOACs) such as apixaban, edoxaban, and rivaroxaban
Trial: 33901518
Drug: Low birthweight
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low birthweight (<2500 g)
Trial: 33657912
Drug: Information Prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Information Prescription (IP) prescribed by the physician plus routine oral information
Trial: 33657912
Drug: Routine oral
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine oral information by nurse or physician (control group)
Trial: 32351061
Drug: Phlogenzym (systemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phlogenzym (systemic enzyme therapy)
Trial: 33783102
Drug: Negative-pressure wound
RxNorm normalized name: Microcyn Negative-Pressure Wound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative-pressure wound therapy with instillation (NPWTi)
Trial: 32593287
Drug: HFNC with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HFNC with oxygen flow rate at 40 L/min
Trial: 32593287
Drug: HFNC with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HFNC with oxygen flow rate at 60 L/min
Trial: 32593287
Drug: HFNC with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HFNC with oxygen flow rate at 40 L/min or 60 L/min
Trial: 34348343
Drug: Chitosan nanoparticle
RxNorm normalized name: Chitosan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chitosan nanoparticle and gum (CN-G) applied twice daily for 4 weeks
Trial: 34348343
Drug: Placebo (gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (gum alone) applied twice daily for 4 weeks
Trial: 35583555
Drug: Venetoclax (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venetoclax (800 mg orally daily) plus Fulvestrant (500 mg intramuscular; cycle 1: days 1 and 15; subsequent 28-day cycles: day 1)
Trial: 34937507
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D deficiency (25(OH)D < 10 ng/ml)
Trial: 36007881
Drug: Creatine Monohydrate
RxNorm normalized name: Creatine Monohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine Monohydrate (5 g/day)
Trial: 36007881
Drug: Creatyl-L-Leucine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatyl-L-Leucine (5 g/day)
Trial: 35793342
Drug: Melatonin supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin supplement
Trial: 35793342
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of physical exercise and melatonin supplement
Trial: 33773532
Drug: Routine chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine chemotherapy care (control group)
Trial: 34473402
Drug: Daily PrEP
RxNorm normalized name: Zinc Oxide 238 mg in 1 mL / Titanium Dioxide 41 mg in 1 mL TOPICAL LOTION [bareMinerals Prep Step Mineral Shield Broad Spectrum SPF 50 Daily Prep]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily PrEP regimen (TDF/FTC 300 mg/200 mg)
Trial: 34473402
Drug: On-demand PrEP
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On-demand PrEP regimen (TDF/FTC 300 mg/200 mg)
Trial: 34269239
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment groups (BCP and xenograft)
Trial: 33357325
Drug: Multicomponent intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multicomponent intervention including inpatient pharmacist‐led medication reconciliation, coordination of care, postdischarge phone calls, and postdischarge primary care visit.
Trial: 32511749
Drug: Tenecteplase 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenecteplase 0.4 mg/kg (maximum 40 mg)
Trial: 32739102
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin (BT) intraanal sphincteric injection
Trial: 32739102
Drug: Bowel management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bowel management program (BMP) and senna based laxatives (SBL)
Trial: 35278093
Drug: Tät II
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tät II treatment focused on pelvic floor muscle training (PFMT) and bladder training (BT)
Trial: 39604382
Drug: Traditional physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional physical therapy program
Trial: 33470755
Drug: Transdermal 17-beta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal 17-beta estradiol (TE) 100 mcg/d
Trial: 33470755
Drug: Oral raloxifene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral raloxifene 60 mg/d
Trial: 33470755
Drug: Proprietary phytoestrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proprietary phytoestrogen compound, Rimostil 1000 mg twice/d
Trial: 32416181
Drug: Elevated baseline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elevated baseline serum uric acid (sUA) levels (>6 mg/dL)
Trial: 34817964
Drug: Adhesive/nanofilled resin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adhesive/nanofilled resin composite restorations (RC; OptiBond FL, Kerr/Filtek Supreme XTE, 3M Oral Care)
Trial: 35505308
Drug: Natremia <
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natremia < 135 mmol/L
Trial: 33132228
Drug: Dabigatran (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dabigatran (150 or 110 mg twice daily)
Trial: 34410769
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (TAU; n = 133).
Trial: 32083994
Drug: Restrictive RBC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive RBC transfusion strategy (Hb threshold < 70 g/L)
Trial: 32083994
Drug: Liberal RBC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liberal RBC transfusion strategy (Hb threshold < 90 g/L)
Trial: 32088018
Drug: Oral rotavirus
RxNorm normalized name: rotavirus vaccine, live attenuated, G1P[8] human 89-12 strain Oral Suspension [Rotarix]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rotavirus vaccine (RVV)
Trial: 32142484
Drug: C+COX‐2‐Is (convention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C+COX‐2‐Is (convention plus COX‐2 inhibitors)
Trial: 37315225
Drug: Any treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any treatment
Trial: 32045773
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (TXA) 1.5 g intra-articular combined with 1.5 g intravenous
Trial: 32045773
Drug: Hemocoagulase atrox
RxNorm normalized name: Crotalus atrox antivenin
DrugBank: Crotalus atrox antivenin (DB13892)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemocoagulase atrox 1 U intra-articular combined with 1 U intravenous
Trial: 34049378
Drug: Intravenous somatostatin
RxNorm normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous somatostatin plus rectal indomethacin (100 mg suppository)
Trial: 34049378
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (rectal indomethacin only)
Trial: 34268406
Drug: High-dose octreotide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose octreotide
Trial: 32460818
Drug: Oral ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ciprofloxacin and co-amoxiclav for at least 5 days after switching from intravenous antibiotics within 12-24 hours of starting IV therapy.
Trial: 32460818
Drug: Intravenous antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous antibiotics (piperacillin/tazobactam or meropenem) continued for at least 48 hours.
Trial: 36344005
Drug: Restrictive oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive oxygen strategy (lowest dosage of oxygen >21% to ensure SpO2 of 94%)
Trial: 36344005
Drug: Liberal oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liberal oxygen strategy (12-15 L O2/min or FiO2 = 0.6-1.0)
Trial: 32967392
Drug: Control (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (standard pain management drugs)
Trial: 35988198
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment + BAL
Trial: 35988198
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment + ST + BAL
Trial: 35988198
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment + ST
Trial: 33370739
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese music therapy
Trial: 33370739
Drug: Painting therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Painting therapy
Trial: 35677742
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D therapy requirement
Trial: 36058207
Drug: Advanced Hybrid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Advanced Hybrid Closed Loop (AHCL) therapy
Trial: 36058207
Drug: Multiple daily
RxNorm normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple daily injections of insulin plus isCGM
Trial: 36058207
Drug: Multiple daily
RxNorm normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple daily injections of insulin plus isCGM group
Trial: 36395746
Drug: Killed oral
RxNorm normalized name: Hongo Killer
DrugBank: Undecylenic acid (DB11117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Killed oral cholera vaccine (OCV) with a second dose after 2 weeks
Trial: 36395746
Drug: Killed oral
RxNorm normalized name: Hongo Killer
DrugBank: Undecylenic acid (DB11117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Killed oral cholera vaccine (OCV) with a second dose after 6 months
Trial: 36395746
Drug: Killed oral
RxNorm normalized name: Hongo Killer
DrugBank: Undecylenic acid (DB11117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Killed oral cholera vaccine (OCV) with a second dose after 11.5 months
Trial: 34209004
Drug: Suspension training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suspension training (n = 12)
Trial: 34504284
Drug: rTMS (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rTMS (20 Hz, 1800 pulses per session) for 4 weeks before lower limb resistance training or physical therapy
Trial: 33754424
Drug: Levobupivacaine HCl
RxNorm normalized name: LEVOBUPIVACAINE HCL
DrugBank: Levobupivacaine (DB01002)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levobupivacaine HCl (5.0 mg/mL) mixed with isotonic solution (4, 6, 8, and 10 mL of levobupivacaine with 26, 24, 22, and 20 mL of isotonic solution, respectively)
Trial: 33754424
Drug: Levobupivacaine HCl
RxNorm normalized name: LEVOBUPIVACAINE HCL
DrugBank: Levobupivacaine (DB01002)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levobupivacaine HCl (5.0 mg/mL) mixed with isotonic solution
Trial: 33754424
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group using Cathejell-2% lidocaine (25 mg lidocaine)
Trial: 34102783
Drug: Intranasal glucocorticoid
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal glucocorticoid (dexamethasone) after nasal endoscopic surgery
Trial: 34102783
Drug: Oral glucocorticoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucocorticoid (prednisone) one week before operation and three weeks after operation
Trial: 34503552
Drug: Autologous hematopoietic
RxNorm normalized name: Autologous Hematopoietic Peripheral Blood Stem Cells
DrugBank: Autologous Hematopoietic Peripheral Blood Stem Cells (DB17067)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous hematopoietic stem cell transplant (AHSCT) treatment
Trial: 34503552
Drug: Modifiable factors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modifiable factors (distance to treatment center and cost)
Trial: 36145115
Drug: 15 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 g of ground raw golden flaxseed
Trial: 33120302
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of haloperidol and ketamine
Trial: 34480579
Drug: Daridorexant 100
RxNorm normalized name: Daridorexant
DrugBank: Daridorexant (DB15031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daridorexant 100 mg
Trial: 39641404
Drug: Daridorexant (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daridorexant (both doses)
Trial: 36295519
Drug: High-dose intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intramuscular vitamin D (cholecalciferol 200,000 IU)